Below are descriptions of the 20 ProActive HavRx global equity indexes that include a database of over 1,000 stocks with links to the Investars YOU website for performance tracking.
http://www.proactivenewsroom.com/indexes/
ImmunoTherapy / Vaccines Index
The actively managed HavRx ImmunoTherapy / Vaccines Index includes companies with market caps below $5 billion at the time of index inclusion which are developing or commercializing any type of immunotherapy, gene therapy, or vaccine product that is designed to stimulate the immune system for the eradication, combination treatment, or prevention of cancer. In addition, the index will track companies which are developing or commercializing any type of vaccine product or vaccine adjuvant for all types of infectious disease such as influenza (flu) and bio-defense applications.
Clean-Tech / Carbon Trading Index
The ProActive Clean-Tech / Carbon Trading Index is actively managed and tracks the performance of companies which either generate carbon credits through their business operations, are involved with the trading of carbon credits, or reduce carbon emissions through their business activities. In addition, the index may include companies that supply renewable energy products, services, and raw materials / resources for applications such as waste-to-energy, landfill / methane gas collection, clean energy / bio-fuels, smart electric grid / power management, energy efficiency, water supply infrastructure, and all other forms of alternative energy such as wind, solar, battery, and hydropower.
Cosmetic / Restorative Medicine Index
The HavRx Cosmetic / Restorative Medicine Index is actively managed and tracks the performance of companies that derive over 50% of revenue from any of the following activities: (1) prescription skin care therapeutics; (2) medical devices, products, services, OR equipment for procedures which are intended to enhance appearance; (3) medical devices, products, services, OR equipment for use as joint replacements, tissue repair agents, tissue reconstruction agents, surgical adhesives, and cardiovascular procedures; and (4) regenerative medicine products, services, and/or an active clinical pipeline which seeks to restore or repair the functionality of lost or damaged organ, tissue, cellular, and genetic material.
Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index
The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with market caps below $500 million at the time of index inclusion, encompassing the following categories: (1) diagnostics (molecular diagnostics and device-based diagnostics), (2) lab services (personalized medicine applications to guide and track the effectiveness of cancer treatments), (3) drug discovery (screening and modifying compounds to achieve anti-cancer effects during the early stages of preclinical and Phase 1 clinical studies), (4) immunotherapy (a.k.a. cancer vaccines which are designed to stimulate the immune system to eradicate cancer), and (5) commercial or late-stage (Phase 2-3) clinical development therapeutics, devices, or diagnostics intended for use by cancer patients.
Emerging Diagnostics Index
The HavRx Emerging Diagnostics Index is actively managed and tracks the performance of companies with market caps below $500 million at the time of inclusion. The index includes diabetes monitoring device makers, laboratory services, clinical diagnostics, diagnostic imaging, diagnostic equipment makers, and molecular diagnostics.
Global Generic Drug Index
The HavRx Global Generic Drug Index is actively managed and tracks the performance of companies which meet any of the following three requirements: (1) Derive either $500 million (USD) OR more than 50% of trailing 12-month revenues from the manufacture and sale of any type of generic (off-patent) prescription or over-the-counter (OTC) drug product intended for use by humans, including contract manufacturing services for drug products and biological agents; (2) Have one or more compound(s) in active clinical development OR have a pending ANDA with the FDA for a generic drug candidate; (3) As an alternative to the revenue requirement, companies may also qualify by receiving FDA approval for an abbreviated new drug application (ANDA) within the past 12 months.
Global Health Information Technology (Health IT) Index
The HavRx Global Health IT Index is actively managed and tracks the performance of companies with market caps below $10 billion that derive over either $50 million or 50% of their trailing 12-month revenue from products and services for the following activities: (1) electronic transmission, storage, and processing of prescriptions; (2) secure e-mail transmission for healthcare facilities; (3) electronic transmission, storage, and processing of medical imaging and diagnostic information; (4) electronic storage and systems for administrative functions of healthcare facilities and medical records; (5) electronic transmission, storage, and systems for healthcare market data and clinical trial data; (6) electronic systems, devices, and services for remote, real-time monitoring of patient health parameters; (7) medical transcription services, products, and systems for conversion into electronic medical records.
Global Stem Cell Index
The HavRx Global Stem Cell Index is actively managed and tracks the performance of regenerative medicine companies (with stock prices of at least 15 cents at the time of inclusion) which derive over 50% of revenue or have compound(s) in active pre-clinical or clinical development which are designed to restore, replace, repair, or enhance the functionality or appearance of tissue and organ systems, including all types of embryonic and adult stem cell therapeutics. In addition, all types of products and services for stem cell banking are included in this index.
Health Benefit Providers Index
The HavRx Health Benefit Providers Index is actively managed and tracks the performance of retail pharmacies, pharmacy benefit managers, managed care companies, health insurers, hospital pharmacy operators, workers compensation insurers, and specialty health benefit providers.
Preventative Medicine Index
The HavRx Preventative Medicine Index is actively managed and tracks the performance of companies with market caps over $100 million at the time of inclusion that derive over either 50% or $100 million in trailing 12-month revenue from any of the following activities: (1) human vaccines which are already on the market or in active clinical development; (2) diagnostics and lab services; (3) diabetes care; and (4) vitamins, health supplements, functional foods, and weight loss products or services.
Regulatory Catalyst Index
The actively managed HavRx Regulatory Catalyst Index tracks the performance of healthcare companies with pending new drug, biological agent, or medical device/diagnostic product decisions at the FDA.
Pet Care / Animal Farma Index
The HavRx Pet Care / Animal Farma Index is actively managed and tracks the performance of companies with market caps below $5 billion at the time of inclusion that are active in the following business segments: animal breeding, animal `pharming`, veterinary stem cells, veterinary services, pet retailers, animal feeds nutrition, and veterinary medicine diagnostics. Favorable growth trends for the pet and animal care industry include (1) pet spending in the U.S. is estimated at $43.4B in 2008, up from $32.4B in 2003; (2) about 63% of U.S. households have a pet, which equals over 71M homes; and (3) the worldwide market for animal healthcare, excluding bulk feed and nutrition products, is expected to reach just under $20B in 2008, experiencing growth of 26% from $15.6B in 2003.
Global Hospital Index
The HavRx Global Hospital Index is actively managed and tracks the performance of companies which derive over 50% of revenue from the following activities: hospitals, inpatient rehabilitation facilities, dialysis facilities, hospice providers, inpatient behavioral healthcare facilities, and ambulatory surgery centers. The revenue requirement for this index excludes the following activities: home healthcare, outpatient medical services, and senior living centers.
Global Air Transport Index
The ProActive Global Air Transport Index is actively managed and tracks the performance of companies that derive over 50% of revenue from passenger airline services, helicopter transport services, and air freight transport activities.
Global Railroad Index
The ProActive Global Railroad Index is actively managed and tracks the performance of companies that derive either more than 50% OR $100 million of trailing 12-month revenue from any of the following activities: (1) passenger or freight rail transport services; (2) railcar and locomotive leasing; (3) railcar and locomotive fleet management; (4) rail infrastructure, railcar, locomotive, and railcar/locomotive component parts manufacturing; (5) railcar, locomotive, and component parts repair or refurbishment.
Global Telecom Services Hi-Dividend Index
The ProActive Global Telecom Services Hi-Dividend Index is actively managed and tracks the performance of companies with market caps over $1 billion at the time of inclusion that meet the following requirements: (1) All such companies must derive at least 50% of their trailing 12-month revenue from any types of voice and data telecom services such as fixed line communications, wireless communications, and internet access provider services and (2) All such companies must have a trailing 12-month dividend yield of at least 1.5%.
Global Tobacco Index
The ProActive Global Tobacco Index is actively managed and tracks the performance of companies which derive over 50% of their revenue from the distribution or manufacturing of any type of tobacco product (e.g. cigarettes, cigars, chewing tobacco) or any related tobacco supplies (e.g. wrapping papers, tobacco leafs, filters).
Global Trucking / Logistics Index
The ProActive Global Trucking / Logistics Index is actively managed and tracks the performance of companies with market caps over $100 million at the time of inclusion that derive at least 50% of trailing 12-month revenue from any of the following activities: logistics and management support services for all types of transportation companies; all types of land-based, roadway freight forwarding freight transportation services; mail package delivery, transportation, and logistics services; and logistics management support services for roadway transportation companies.
Global Metals / Mining Index
The ProActive Global Metals / Mining Index is actively managed and tracks the top-rated companies with market caps over $1 billion upon inception that derive over 50% of revenue from the exploration, mining, extraction, processing, and sale of all types of precious metals, minerals, and industrial metals. The top rated companies are chosen based on their trailing 12-month stock price performance, market cap weighting, and net income weighting.
Nation Cap Leaders Index
The ProActive Nation Cap Leaders Index is actively managed and tracks the performance of companies that are market cap leaders from each nation (at least $5 billion), including developed, emerging, and frontier markets.
$28.71 (10/23/09)
